Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Chemical Basis for Qualitative and Quantitative Differences Between ABO Blood Groups and Subgroups: Implications for Organ Transplantation.

Jeyakanthan M, Tao K, Zou L, Meloncelli PJ, Lowary TL, Suzuki K, Boland D, Larsen I, Burch M, Shaw N, Beddows K, Addonizio L, Zuckerman W, Afzali B, Kim DH, Mengel M, Shapiro AM, West LJ.

Am J Transplant. 2015 May 26. doi: 10.1111/ajt.13328. [Epub ahead of print]

PMID:
26014598
2.

ING3 protein expression profiling in normal human tissues suggest its role in cellular growth and self-renewal.

Nabbi A, Almami A, Thakur S, Suzuki K, Boland D, Bismar TA, Riabowol K.

Eur J Cell Biol. 2015 May;94(5):214-22. doi: 10.1016/j.ejcb.2015.03.002. Epub 2015 Mar 14.

PMID:
25819753
3.

Validation of the firefighter WFI treadmill protocol for predicting VO2 max.

Dolezal BA, Barr D, Boland DM, Smith DL, Cooper CB.

Occup Med (Lond). 2015 Mar;65(2):143-6. doi: 10.1093/occmed/kqu189. Epub 2015 Jan 7.

PMID:
25567508
4.

Reduction of U(VI) by Fe(II) during the Fe(II)-accelerated transformation of ferrihydrite.

Boland DD, Collins RN, Glover CJ, Payne TE, Waite TD.

Environ Sci Technol. 2014 Aug 19;48(16):9086-93. doi: 10.1021/es501750z. Epub 2014 Jul 21.

PMID:
25014507
5.

Validation of heart rate derived from a physiological status monitor-embedded compression shirt against criterion ECG.

Dolezal BA, Boland DM, Carney J, Abrazado M, Smith DL, Cooper CB.

J Occup Environ Hyg. 2014;11(12):833-9. doi: 10.1080/15459624.2014.925114.

PMID:
24896644
6.

Effect of solution and solid-phase conditions on the Fe(II)-accelerated transformation of ferrihydrite to lepidocrocite and goethite.

Boland DD, Collins RN, Miller CJ, Glover CJ, Waite TD.

Environ Sci Technol. 2014 May 20;48(10):5477-85. doi: 10.1021/es4043275. Epub 2014 Apr 30.

PMID:
24724707
7.

Synthesis and characterization of antibacterial silver nanoparticle-impregnated rice husks and rice husk ash.

He D, Ikeda-Ohno A, Boland DD, Waite TD.

Environ Sci Technol. 2013 May 21;47(10):5276-84. doi: 10.1021/es303890y. Epub 2013 May 9.

PMID:
23614704
8.

How patient beliefs affect adherence to prescribed medication regimens.

Chummun H, Boland D.

Br J Nurs. 2013 Mar 14-27;22(5):270-6.

PMID:
23545553
9.

Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.

Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group.

Diabetes Care. 2013 Aug;36(8):2162-8. doi: 10.2337/dc12-1391. Epub 2013 Feb 14.

10.

Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis.

Swortwood MJ, Boland DM, DeCaprio AP.

Anal Bioanal Chem. 2013 Feb;405(4):1383-97. doi: 10.1007/s00216-012-6548-8. Epub 2012 Nov 23.

PMID:
23180084
11.

The economic and quality of life burden associated with Parkinson's disease: a focus on symptoms.

Boland DF, Stacy M.

Am J Manag Care. 2012 Sep;18(7 Suppl):S168-75. Review.

12.

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators.

Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14.

13.

Domain recognition of the ING1 tumor suppressor by a panel of monoclonal antibodies.

Suzuki K, Boland D, Gong W, Riabowol K.

Hybridoma (Larchmt). 2011 Jun;30(3):239-45. doi: 10.1089/hyb.2010.0124.

PMID:
21707358
15.

Evaluating the outcomes of a distance-accessible PhD program.

Broome ME, Halstead JA, Pesut DJ, Rawl SM, Boland DL.

J Prof Nurs. 2011 Mar-Apr;27(2):69-77. doi: 10.1016/j.profnurs.2010.09.011.

PMID:
21420038
16.

Long-term effects of intensive glucose lowering on cardiovascular outcomes.

ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT.

N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.

17.

Effect of amorphous Fe(III) oxide transformation on the Fe(II)-mediated reduction of U(VI).

Boland DD, Collins RN, Payne TE, Waite TD.

Environ Sci Technol. 2011 Feb 15;45(4):1327-33. doi: 10.1021/es101848a. Epub 2011 Jan 6.

PMID:
21210678
18.

Static foot posture associated with dynamic plantar pressure parameters.

Teyhen DS, Stoltenberg BE, Eckard TG, Doyle PM, Boland DM, Feldtmann JJ, McPoil TG, Christie DS, Molloy JM, Goffar SL.

J Orthop Sports Phys Ther. 2011 Feb;41(2):100-7. doi: 10.2519/jospt.2011.3412. Epub 2010 Oct 22.

PMID:
20972342
19.

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group.

Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4. Epub 2010 Jun 30. Erratum in: Lancet. 2010 Oct 30;376(9751):1466.

20.

Effects of medical therapies on retinopathy progression in type 2 diabetes.

ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ.

N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. Erratum in: N Engl J Med. 2011 Jan 13;364(2):190. N Engl J Med. 2012 Dec 20;367(25):2458.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk